Wegovy Weight-Loss Results: Trials, Timeline and Evidence

Research analysis

Wegovy Weight-Loss Results: Trials, Timeline and Evidence

Why there is no one Wegovy result

A headline percentage can conceal baseline population, diabetes status, formulation, duration, comparator, endpoint definition and continuation status. Mean percentage change is also different from the proportion of participants crossing 10%, 15% or 20% thresholds.

STEP evidence

The STEP clinical-development program established injectable semaglutide as a major obesity-treatment intervention. Across the program, substantial average weight reductions were observed, but individual trials studied different populations and follow-up periods. That is why one-year, two-year and maintenance searches should not be collapsed into one number.

Weight-loss timeline

Weight change in trials is generally progressive rather than immediate. A result observed after several months should not be converted into a simple weekly or monthly forecast. The useful research question is the trajectory reported by the relevant trial.

Continuation and regain

Peak weight loss and long-term maintenance are separate endpoints. Across GLP-1 research, treatment withdrawal can be followed by regain. Maximum on-treatment results should therefore not be described as automatically permanent after cessation.

Wegovy versus Zepbound

SURMOUNT-5 directly compared tirzepatide with semaglutide rather than relying on unrelated trials. Adults with obesity without type 2 diabetes were randomized for 72 weeks, and tirzepatide was superior for reduction in body weight and waist circumference. NEJM. This strengthens the comparative evidence but does not create a universal treatment recommendation.

Oral Wegovy changes the results question

The arrival of oral Wegovy means future search results must distinguish daily oral semaglutide from weekly injected semaglutide. EMA's 2026 regulatory record addresses oral Wegovy development, and current US labeling also includes tablets. EMA.

Wegovy HD

Wegovy HD adds another layer to results research. FDA approved the 7.2 mg injection in March 2026. Higher-dose evidence should therefore be discussed as its own product-development topic rather than folded into standard Wegovy results.

Cardiovascular outcomes should stay separate

Weight change and cardiovascular-risk reduction are different endpoints. Wegovy's cardiovascular evidence supports reduction in major events in a specified population. That outcome should not be presented as simply another weight-loss percentage.

Why body composition can matter

Scale weight is a useful endpoint but does not describe how fat mass, lean mass and other tissues change. Where high-quality body-composition data are available, they can provide a more informative view than total weight alone.

Why direct comparisons are stronger than cross-trial comparisons

Comparing a STEP headline with a SURMOUNT headline can be misleading because the populations, protocols and endpoints may differ. A head-to-head trial reduces some of that uncertainty by placing both active treatments under the same protocol.

What remains uncertain?

Long-term formulation-specific durability, repeated interruption, very-long-term maintenance, real-world adherence and comparative outcomes between oral, standard injectable and HD formulations remain important research questions.

Why one-year and longer evidence deserve separate treatment

Short-term results can show the early direction of weight change, while longer trials answer different questions about continuation, plateau, durability and treatment persistence. A one-year result should not simply be extrapolated to two years, and a longer trial should not be reduced to a monthly average. The final page therefore treats duration as part of the evidence rather than a footnote.

Why study population changes the expected average

People with obesity without diabetes, people with type 2 diabetes, adolescents and adults with established cardiovascular disease can produce different weight trajectories. Baseline weight, metabolic status and study eligibility all influence group averages. A result from one population should not be silently transferred to another.

Why threshold outcomes can be more useful than a mean

An average percentage can conceal wide variation between participants. Reporting the share of participants reaching clinically meaningful thresholds can add another perspective on efficacy. Mean change and threshold achievement answer different questions and should be presented side by side rather than treated as interchangeable.

Why results should be presented as ranges of evidence rather than promises

Clinical trials are designed to estimate average effects under defined conditions, not to predict exactly what will happen to an individual reader. Variation can arise from baseline weight, metabolic health, adherence, duration, concomitant conditions and many other factors. A strong research page therefore answers the high-intent question directly while preserving uncertainty. It can report the direction and magnitude seen in studies, explain how many participants reached specific thresholds and compare treatments where direct evidence exists, without converting population averages into personal forecasts.

Sources and references

• SURMOUNT-5
• FDA Wegovy prescribing information
• EMA Wegovy regulatory record
• FDA Wegovy HD announcement

Research governance: methodology · editorial policy · corrections · medical disclaimer.